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Influenza and the Implications
of a Pandemic for Malta
Gianfranco Spiteri, Ryan Farrugia, Tanya Melillo Fenech
Abstract
An influenza pandemic is inevitable and recent reports from
Southeast Asia on avian influenza viruses infecting humans
have served to fuel worries that a new pandemic is near.  The
purpose of this article is to provide an overview of the
epidemiological and public health aspects of seasonal, avian
and pandemic influenza through a literature review and to
describe the possible effects of an Influenza pandemic on Malta
using the FluAid model.
The results of the model indicate that between 158 and 454
deaths would be expected for a 12-week pandemic causing
clinical symptoms in 25% of the population. There would be
between 432 and 1,488 hospitalisations and between 40,483
and 74,704 general practice consultations.
Although the results of the model show a wide range of
estimates and are limited by a lack of local parameters, the data
presented in this article shows the severe effect of a pandemic
on the Maltese health care system and will be useful for
pandemic planning. Further research needs to be undertaken
to determine local parameters to improve the model estimates
and local health authorities need to ensure that adequate
resources are provided to implement an effective pandemic
preparedness plan.
Introduction
The twentieth century was the setting for three major
influenza pandemics. The 1918-19 pandemic killed an estimated
40 million people, mainly young adults;1  in contrast the First
World War killed about 15 million. The 1957-58 and 1968-69
pandemics, although milder, killed a total of 1.5 million people.
With the emergence of the H5N12 and H9N23 strains in the Far
East, the World Health Organisation (WHO) has emphasised
the importance of planning for a forthcoming pandemic.4 Whilst
nobody can forecast when another pandemic will start, the signs
are ominously similar to what is thought to have happened prior
to earlier pandemics.
The purpose of this article is to review the available evidence
and provide an overview of influenza, its treatment and
prevention options and use a static model to describe the
possible effects of the first wave of an influenza pandemic on
the Maltese population and on healthcare resources.
Classification
Influenza viruses are enveloped RNA viruses with a
segmented genome belonging to the family Orthomyxoviridae.
They are classified into three main types, A, B and C, based on
their core proteins. Influenza C is poorly understood and
probably of limited clinical significance.  Strains are named
according to the type, geographical site of isolation, strain serial
number, year of isolation, and, for Influenza A, according to
the Haemagglutinins (HA) and Neuraminidases (NA) in that
order. So, for example, the WHO recommends that the seasonal
vaccine for 2005-2006 should contain the following strains: A/
New Caledonia/29/99(H1N1)-like virus, A/California/7/
2004(H3N2)-like virus and B/Shangai/361/2002-like virus.5
There are a number of Influenza A strains based on different
combinations of 16 H subtypes and 9 N subtypes.6  Strains with
all different combinations are known to exist in waterfowl,
whereas only H1 to 3 and N 1 to 2 subtypes commonly exist in
humans. H1N1, H3N2 and H1N2 influenza A viruses and
Influenza B viruses are currently circulating.7
Antigenic shift and drift
Frequent development of antigenic variants through
antigenic drift is the virologic basis for seasonal epidemics and
the reason for the incorporation of one or more new strains in
each year’s influenza vaccine. New virus variants occur every
season due to point mutations resulting in antigenic drift. This
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is mainly due to the infidelity of RNA polymerase and selective
pressures from host immune responses. Pandemic viruses
result from antigenic shift. This happens when reassortment
(facilitated by the segmented genome) of a human influenza
strain with a strain which had not previously caused disease in
humans leads to a virus having heamaglutinin or
neuramidinase proteins to which the majority of humans do
not have antibodies. Immunity to the surface antigens, mainly
to HA, reduces the risk of infection and the severity of illness.8
Antibody to one antigenic type or subtype does not completely
protect against a new antigenic variant of the same type or
subtype.9
Illness due to influenza viruses
Illness due to influenza virus is characterised by the abrupt
onset of symptoms, mainly fever, malaise, dry cough, myalgia,
headache, sore throat and rhinitis. Constitutional symptoms
are marked. Children can also present with nausea, vomiting
and otitis media. The incubation period for influenza ranges
from 1-4 days with a mean of two days.10  Adults are infective
from the day before symptoms start and for 5-7 days after onset.
Children are known to shed virus from six days before onset of
symptoms, to more than 10 days after onset.
Immunocompromised children may shed virus for months.11,12
Illness lasts between 3-7 days, although malaise and cough can
last for over two weeks.13  Influenza causes significant morbidity
and mortality through the exacerbation of underlying medical
conditions. Secondary bacterial or primary viral pneumonia
may also occur. In children, illness may mimic bacterial sepsis
with high fevers and may also cause seizures, encephalitis and
Reye’s syndrome.7 Symptoms are very non-specific and the
sensitivity and specificity of clinical diagnosis depends on the
level of influenza activity as well as the degree of circulation of
other respiratory viruses.14
Hospitalisations and Mortality
Estimates of hospitalisation due to influenza-related illness
vary by age-group and by the severity of the season studied.
Highest risk is seen in adults aged over 65 years and in children
aged less than one year.7  Over 63% of hospital admissions due
to influenza-related illnesses are for persons aged >65 years.15
In the United States, the highest numbers of hospital
admissions have occurred in years when H3N2 viruses were
circulating.16  Mortality due to influenza related illness has been
estimated at 0.4 deaths per 100,000 persons in the 0-49 years
age-group, 7.5 in persons aged 50-64 and 98.3 among persons
aged >65 years.17 Deaths in children are rare, but do occur.18
Vaccine
Estimates of effectiveness of seasonal vaccine have varied
between studies. In years when vaccine viruses and the
circulating strain were well matched, the inactivated vaccine
has been shown to prevent illness in 70-90% of healthy adults
aged <65 years.19,20 Effectiveness in years when the strains were
poorly matched was 52% in healthy adults and 38% among
adults with high-risk conditions.21
In children, the effectiveness increases with age. Healthy
children aged over six months can develop protective levels of
antibody after vaccination22 but it is thought that children with
diseases which make them at high-risk for influenza-related
complications might have a poorer antibody response.23 Vaccine
effectiveness in children increases with age24 and varies with
the degree of match. It is lower in milder flu seasons.7 There is
some evidence that seasonal vaccine reduces the incidence of
otitis media by around 30%. 25
In adults aged >65 years and persons with chronic diseases,
immunogenicity may be poor. 26,27  Randomised studies have
shown an efficacy of 58% in preventing clinical influenza in this
age-group. The authors report that efficacy might be lower in
persons aged >70 years.28 The most important effect of influenza
vaccine in older people lies in decreasing influenza-related
hospitalisation and death, particularly in residents of nursing
homes. In >65 year olds not living in nursing homes, with or
without chronic conditions, influenza vaccine prevents 30-70%
of hospitalisations due to pneumonia or influenza. 29,30 In those
living in nursing homes, influenza vaccine is 30-40% effective
in preventing clinical influenza, 50-60% effective in preventing
influenza-related hospitalisation and 80% effective in
preventing influenza-related death.31,32,33
Antivirals
Antivirals can be useful as an adjunct to vaccination in
preventing and treating influenza. However, they should not
be considered as an alternative to vaccination.8 Options for
treatment of clinical influenza have increased in recent years
with the development of neuraminidase inhibitors.
Amantadine is licensed in the UK for use in adults and
children over 10 years of age. It is only effective against Influenza
A and has a number of contraindications and drug interactions.
Influenza A strains can quickly develop resistance to
amantadine. Currently in the UK, about 2.3% of circulating
influenza viruses exhibit amantadine resistance. Studies have
reported that up to one third of patients shed resistant strains
when treated with amantadine.34
Zanamivir is a neuraminidase inhibitor and is licensed in
the UK for the treatment of influenza A and B in people aged
12 years or older, if given within 48 hours of the onset of
symptoms, when influenza is circulating. Zanamivir is
contraindicated in breastfeeding women and should be used
with caution in people with asthma or chronic pulmonary
disease because of risk of bronchospasm. It has been reported
that after tuition 50% of patients were unable to load and prime
the diskhaler and 65% were unable to do so 24 hours later. 35
Oseltamivir is also a neuraminidase inhibitor and unlike
zanamivir, it can be taken orally. Side effects are uncommon.
In the UK, oseltamivir is licensed for the treatment of influenza
A and B in people of 1 year of age or older, within 48 hours of
the onset of symptoms, when influenza is circulating. The dose
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of oseltamivir should be adjusted for people with severe renal
impairment.  Resistance to the neuraminidases has been
reported.  However, the resistant strains do not appear to be of
increased virulence. Only 0.4% of Influenza A strains and no
Influenza B strains taken from patients not being treated with
oseltamivir in Japan were reported to be resistant to oseltamivir
in a recent investigation.36
The NICE report did not find convincing evidence that
amantadine reduces the frequency of hospitalisations and
complications of influenza, particularly among high-risk groups.
The authors thus do not recommend treatment with
amantadine, as this is not cost-effective and rapidly leads to the
development of resistance. The guidelines state that for the
neuraminidases to be cost-effective, their use should be
restricted to treatment of high-risk patients (zanamivir for
adults only and oseltamivir for adults and children) during times
when influenza virus is known to be circulating in the
community.
A systematic review showed that treating otherwise healthy
adults and children with zanamivir and oseltamivir reduces the
duration of symptoms by between 0.4 and 1.0 days and reduces
the odds of complications requiring antibiotics by 29% to 43%
when these are given within 48 hours of onset of symptoms.37
There are still questions, however, about the effectiveness of
antivirals in the prevention of influenza-related morbidity and
mortality among high-risk groups. In one of the few studies
reporting on this aspect, Kaiser et al found that oseltamivir
reduces the incidence of lower respiratory tract complications
by 34% in high-risk groups and reduces all-cause hospitalisation
by about 59%.38
Antivirals have also been licensed in the United States and
United Kingdom for prophylaxis. They are very effective in
preventing clinical influenza, with one 6-week study of
oseltamivir prophylaxis in a nursing home reporting a 92%
reduction in influenza illness.39
Avian Influenza
Avian influenza, then known as bird plague, was first
reported in Italy around the end of the 19th century when a
number of outbreaks were reported.40 Influenza viruses can
cause varying disease severity in birds. Most subtypes cause mild
illness in poultry, but outbreaks involving H5 and H7 subtypes
can have a mortality close to 100% in chickens over 2-12 days.
In recent years there have been increasing reports of avian
influenza virus being transmitted to humans. The Hong Kong
outbreak in 1997 of an H5N1 strain involved 18 cases with six
fatalities.41 An outbreak in the Netherlands in 2003 of a highly
pathogenic strain of H7N7 caused infection in 89 persons,
(symptoms mainly of conjunctivitis), and a veterinarian died
after developing acute respiratory distress syndrome.42,43 Since
2004, there have been three waves of human cases of H5N1 in
Cambodia, Thailand and Vietnam, with 112 cases reported to
WHO until 5 August 2005 and a mortality of 51%.44 Recently,
possible human clusters have also been reported in Indonesia.45
Genotype Z is currently the predominant circulating strain
in Southeast Asia and is reported to be resistant to amantadine.46
There is evidence that limited human-to-human transmission
is occurring; however this appears to be relatively inefficient.47,48
Epidemiological studies have shown that the major risk factor
is contact with poultry and this is facilitated in Southeast Asia
by the numerous backyard farms. It is thus unlikely that the
current outbreaks will end in the near future.49,50
Oseltamivir and zanimivir are so far effective against H5N1
viruses in vitro and in mouse models. Mortality is reported to
increase in mouse models with delay in treatment.51 As a result,
many developed countries are stockpiling neuraminidases for
treatment of patients and in some cases for prophylaxis. Reports
have suggested that Australia, for example, has stockpiled
enough antivirals to protect 200,000 front-line workers
prophylactically for 50 days during a pandemic.52
Pandemic influenza
Ten influenza pandemics have been identified through
clinical and epidemiological records in the past 300 years, with
an average of one every 33 years. In the twentieth century
pandemics did not occur with such regularity, however, with
three major pandemics in 1918-19, 1957-58, 1968-69 and a
relatively minor one in 1977-78. Viral and seroprevalence studies
show that these pandemics were caused by H1N1 (1977), H3N2
(1968), H2N2 (1957), H1N1 (1918), possibly H3N8 (1900) and
H2N2 (1889).50
Table 2: Percentage of population at high risk
of influenza-related complications by age group
Age Group (years) Percentage at high risk
0-19 6.4
20-64 14.4
≥65 40.0
Table 1: Population of Malta and distribution by risk and age-group
0-18yrs 19-64yrs 65+yrs Total % total
Non-High Risk 80,927 215,965 31,148 328,039 84%
High Risk 5,533 36,330 20,765 62,629 16%
Totals 86,460 252,295 51,913 390,668 100%
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Based on information from previous pandemics, it is thought
that a pandemic will first originate in Asia. Once the pandemic
strain becomes adapted to human-to-human transmission,
there will first be small localised outbreaks which will eventually
spread along major trade routes, initially affecting the larger
metropolis before spreading widely.53 The UK Department of
Health (DOH) estimates that the first cases be detected in the
UK within three months of the pandemic strain appearing.54
This is probably a conservative estimate as shown by the rapid
spread of the SARS outbreaks of 2003. DOH estimates that it
will take ten weeks for flu activity to reach the UK threshold for
baseline activity and a further 2-4 weeks for high levels to be
established throughout the country.
The timing of pandemics has been highly variable. Peak
illness during the 1918-19 pandemic was seen in the UK in July.
The second (worse) wave had peaks of illness in November. The
1968/69 pandemic had a first wave around March/April and a
second one in January 1970. The length of the pandemic is
impossible to predict. Pandemics in the last century have been
of variable lengths and generally consisted of two or more waves
of infections with each wave lasting 3-5 months. The second
wave is usually more severe.
Effect on Malta
In the case of Malta, it is conceivable that the first cases
would be seen some weeks after the appearance of outbreaks in
larger European capitals. However, the high density of people
on the island might make conditions for spreading of the virus
easier and we could thus see high levels of activity sooner than
other countries. First reported cases are likely to be travellers
from affected countries. It is likely that once pandemic influenza
is established in Malta, sporadic cases will first appear, then
eventually small outbreaks possibly affecting places like schools
and nursing homes, then leading on to more widespread activity.
Morbidity and mortality is likely to be high, and the strain
on resources will be significant. In this section of the paper, we
use static pandemic models to estimate the expected effect of
the first wave of an influenza pandemic on Malta and on health
care resources in the country. This data will be useful to decision-
makers involved in pandemic planning.
Methods
The effect on Malta was estimated using the FluAid55 and
FluSurge 56 models. The FluAid model requires the user to input
minimum, most likely and maximum estimates of some
variables (eg: influenza-related hospitalisation rates and
mortality rates). This model is based on the one used by Meltzer
et al  to describe the economic effects of a pandemic and different
response strategies.57  The major differences are that the FluAid
model does not use Montecarlo methodologies to estimate the
most likely values. The FluAid model was used to estimate
mortality and general practice consultations. The FluSurge
model, which is based on the FluAid software, is used to estimate
the burden of hospitalisations throughout the pandemic period.
The National Statistics Office provided population estimates
(www.nso.gov.mt). A number of assumptions have been made
in order to arrive to our results. We assume that the pandemic
will be of a single wave lasting 12 weeks. As no data is readily
available for Malta, we assume that the percentage of high-risk
persons is the same as in the United States of America
(Table 1). We also use estimates of mortality and hospitalisation
rates for influenza as used by Meltzer et al (Tables 2 and 3).
Their data was taken from estimates of the Advisory Committee
on Immunization Practices (USA).
We estimated that St.Luke’s Hospital has about 825 beds
(regular capacity excluding social cases) and that the Intensive
Therapy (ITU) and High Dependency Units (HDU) have a total
of 25 staffed beds available. These estimates were reached from
the Annual Report of the Institutional Health Department for
Table 3: Estimates of hospitalisation, mortality and
General Practice consultation rates (per 1000 persons)
used in calculating results (Advisory Committee on
Immunization Practices, USA)
Age Group (years) Hospitalisation rates (not high risk)
Minimum Mean Maximum
0-19 0.2 0.5 2.9
20-64 0.18 1.465 2.75
≥65 1.5 2.25 3
Hospitalisation rates (high risk)
Minimum Mean Maximum
0-19 2.1 2.9 9
20-64 0.83 2.99 5.14
≥65 4 8.5 13
Age Group (years) Mortality rates (not high risk)
Minimum Mean Maximum
0-19 0.014 0.024 0.125
20-64 0.025 0.037 0.09
≥65 0.28 0.42 0.54
Mortality rates (high risk)
Minimum Mean Maximum
0-19 0.126 0.22 7.65
20-64 0.1 2.9 5.72
≥65 2.76 4.195 5.63
Age Group (years) GP Consultation rates (not high risk)
Minimum Mean Maximum
0-19 165 197.5 230
20-64 40 62.5 85
≥65 45 59.5 74
GP Consultation (high risk)
Minimum Mean Maximum
0-19 289 346 403
20-64 70 109.5 149
≥65 79 104.5 130
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200458 that gives an adjusted mean hospital stay for inpatients,
the total number of admissions to St Luke’s Hospital and an
overall occupancy rate. A similar method was used to calculate
the number of ITU and HDU beds available. We estimated that
there are 250 general practitioners in Malta and that they would
be able to see 4 patients more than their usual load every day.
There is no established research or official statistics to prove
these numbers; however discussions with general practitioner
colleagues confirm that this is a reasonable estimate.
Furthermore the following assumptions were made to
produce the results (these estimates were used by the Centre
for Disease Control, USA for regional projections):
• Mean duration of hospitalisation due to influenza-related
illness was assumed to be one week.
• Mean duration of stay in the Intensive Care Unit was
assumed to be 10 days and an average of 15% of hospitalised
cases were assumed to need intensive care.
• The distribution of cases in time is assumed to follow a
roughly normal distribution.
Attack rates varying from 15% to 30% were modelled.
Results
The models produce a range of results for each variable,
describing the most likely, minimum and maximum values. We
will discuss the results of the most likely values for an attack
rate of 25%. The most-likely, minimum and maximum results
for attack rates of 15%, 25% and 30% are reproduced in the
tables.
If no intervention is made (ie: no vaccine is available and
no antivirals are used) with a 25% attack rate, the model
estimates 276 deaths in the most likely scenario but deaths can
vary between 158 and 454 (Table 4). This would mean a
mortality rate of 0.28% for clinical influenza in the most likely
scenario.  Eighty-three percent of deaths will be in high-risk
groups (Table 7). Few deaths are estimated to occur in the
Table 4: Predicted deaths with different attack rates
(including minimum and maximum estimates)
per age-group
Deaths
Attack Rates 15% 25% 35%
0-18 yrs most likely 1 2 3
minimum 1 1 2
maximum 19 31 44
19-64 yrs most likely 79 132 184
minimum 11 19 26
maximum 148 247 346
65+ yrs most likely 85 142 199
minimum 83 138 193
maximum 106 176 246
Total: most likely 165 276 386
Total: minimums 95 158 221
Totals: maximums 273 454 636
Table 5: Predicted hospitalisations with different attack
rates (including minimum and maximum estimates)
per age group
Hospitalisations
Attack Rates 15% 25% 35%
0-18 yrs most likely 26 43 60
minimum 13 21 30
maximum 108 180 252
19-64 yrs most likely 456 761 1,065
minimum 84 141 197
maximum 498 830 1,162
65+ yrs most likely 227 378 530
minimum 162 270 379
maximum 287 478 669
Total: most likely 709 1,182 1,655
Total: minimums 259 432 606
totals: maximums 893 1,488 2,083
youngest age-group and the number of deaths in adults aged
19-64 years will be almost as high as the number of deaths in
>65 year olds. Peak number of deaths will be seen during weeks
8 and 9, when the model estimates that about 41 persons per
week will be dying, 29 of which in hospital (Table 8).
In terms of hospitalisations, the majority will be low-risk
patients (70%) and 54% will be from the 18-65 year age group
(Table 7). The model estimates nearly 1400 hospitalisations
during the 12-week period in the most likely scenario (Table 5).
The peak in admissions will be in weeks 6 and 7, when over 200
patients per week will be admitted due to influenza related
illnesses. Nearly 27% of hospital beds will be needed for patients
admitted due to influenza-related complications (219 during the
peak in week 7). During weeks 7 and 8, the Intensive Care Unit
will have about 45 patients per week due to influenza-related
complications (Table 8).
There will be more than 52,000 GP consultations (Table 6)
and these will be mainly low-risk adults aged 19-64 years (62%
of all consultations).  General practitioners will need to see 208
patients each during the 12-week period, with 32 influenza
patients per week during the peak weeks (Table 8).
Discussion
The data presented above is based on a model that has been
used in a number of countries to estimate the burden of an
influenza pandemic.59,60 There are a number of limitations with
the data, not least of which is the large number of unknown
variables when calculating these estimates. The model does not
take into account the possible varying distribution of cases
between different age groups. During the 1918 pandemic, for
example, attack rates were significantly higher in children and
young adults. The estimates presented also do not take into
account the effect of antivirals, vaccines and other public health
measures. The length of the first wave was assumed to be 12
weeks. This could be an underestimate; however a shorter
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Table 7: Percentage of consultations, hospitalisation and
deaths by risk group
Age Group High Risk Low Risk Total
Consultations
0-18 yrs 3% 23% 26%
19-64 yrs 8% 53% 61%
65+ yrs 5% 8% 13%
Total 16% 84% 100%
Hospitalisations
0-18 yrs 1% 3% 4%
19-64 yrs 10% 54% 64%
65+ yrs 20% 12% 32%
Total 30% 70% 100%
Mortality
0-18 yrs 0% 1% 1%
19-64 yrs 41% 6% 47%
65+ yrs 42% 10% 52%
Total 83% 17% 100%
Table 6: Predicted consultations with different attack
rates (including minimum and maximum estimates)
per age group
Consultations
Attack Rates 15% 25% 35%
0-18 yrs most likely 8151 13,585 60
minimum 6810 11,350 30
maximum 9493 15,821 252
19-64 yrs most likely 19,048 31,747 44,446
minimum 13,677 22,795 31,913
maximum 29,074 48,457 67,840
65+ yrs most likely 4,030 6,716 9,403
minimum 3,803 6,338 8,873
maximum 6,256 10,426 14,596
Total: most likely 31,229 52,048 72,868
Total: minimums 24,290 40,483 56,675
Totals: maximums 44,823 74,704 104,586
pandemic would have a more acute effect on healthcare services
and thus might be considered appropriate for planning.
Despite the uncertainties inherent in making such
predictions, some of the results presented above and the
information on seasonal influenza have clear implications for
pandemic planning. Persons with conditions making them at
high risk for influenza-related complications will be
disproportionately affected. This group generally accounts for
about 15% of the population but will account for 85% of the
mortality and 31% of hospitalisations even though they will
only account for 16% of general practice consultations. It is
also important to note that the mortality rate in the >65 years
age group will have the most significant effect on the final death
toll. It is therefore essential to have plans for dealing with places
such as nursing and residential homes, which have a high
proportion of high-risk >65 year olds. Furthermore, if
availability of vaccines and antivirals is limited (as is likely),
then these groups should be targeted early with specific
strategies.
Hospital capacity will be overwhelmed even in case of a
mild pandemic. Nearly 30% of all hospital beds will be needed
for use for patients admitted due to influenza-related
complications during the peak weeks. Whilst the postponing
of non-urgent surgery and the use of makeshift wards might
reduce coping problems, specialised services such as intensive
care facilities and ventilators will be very badly hit. In a
situation when intensive care beds are already at a premium,
it is necessary to create algorithms and define a priori
guidelines for admissions to intensive care. The actual effect
on hospital resources could be even worse as the model does
not calculate the effect of staff sickness levels on health care
provision. During the 1957 pandemic, for example, nearly a
third of nurses were absent during the peak week in one
Liverpool hospital.54
A shorter pandemic will not mean a decrease in the number
of deaths, unless there is a lower attack rate, but it will result
in an even more severe shortage of hospital beds, equipment
and strain on health service providers. Thus interventions
which aim to slow down spread, such as closing of schools,
churches, discotheques and other meeting places will have a
place in pandemic planning, even though this should be
balanced against the effects of preventing working parents of
school-children from being economically active. A recent study
found that school closure reduced the diagnosis of respiratory
infections by over 40% in children aged 6-12 years. 61 The role
of children in spreading influenza viruses is well known.62
Antivirals will play an important role in combating the
pandemic until a vaccine is developed. A recent study has
indicated that even without the use of vaccines, a stockpile of
antivirals for 20% of the population will reduce mortality by
53% in a three-wave pandemic with characteristics similar to
that of 1918-19.63  Lower attack rates would mean that smaller
stockpiles of antivirals would be needed. Antivirals would
reduce the burden of a pandemic both by directly decreasing
morbidity and mortality but also by reducing circulation of
influenza virus (they do not prevent infection, and thus would
allow build up of immunity and reduce the period of infectivity
by about one day). In any case, it is essential that antivirals are
taken within 48 hours of symptoms starting as effectiveness
decreases quickly with any delays. Plans must therefore include
methods for their quick and widespread distribution as any
bureaucratic delays will lead to preventable deaths. Guidelines
need to be issued on the use of antivirals, both during seasonal
epidemics and in pandemics. Such guidelines should consider
the fact that antivirals are most cost-effective when used in
high-risk groups during seasonal epidemics and that
widespread prescribing of these drugs could also potentially
lead to resistance.
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Other questions remain regarding planning in Malta. Most
European countries have had a functioning sentinel surveillance
system for influenza for years. The UK system for example, has
been running for the past three decades. On the other hand, the
surveillance system in Malta is hampered by a lack of laboratory
facilities (although this is reported to change soon) and a lack
of funding and adequate staffing of the sentinel general practice
system. The sentinel surveillance system was set up for the last
two influenza seasons.  However, due to the above issues, data
has not been consistently provided, and the timeliness of the
system needs to be improved. Unless such a system is working
efficiently during a normal influenza season, it is highly
improbable that it will cope during a pandemic. General
practitioners, on the other hand, need to be involved more
closely in this system and provide much needed data to the
Public Health Department. The regular and widespread
distribution of results from this system to both private and
government general practice doctors would allow better
planning and deployment of resources both during a seasonal
epidemic and in the event of a pandemic.
Protocols need to be set up for the investigation and
management of clusters of respiratory illness in the community,
particularly within nursing homes, closed institutions and
schools. This duty lies within the Public Health realm; however
general practitioners should be aware of the importance of
informing the department about such clusters. Unless these
investigations are made standard practice during in the inter-
pandemic period, there is no reason to believe these will be done
effectively once a pandemic starts. Effective management of
influenza outbreaks in closed settings even during the
interpandemic period can lead to decreased morbidity64 and
possibly mortality.
Lack of local data makes estimating the effect of, and
planning the response to, a pandemic difficult and imprecise.
Besides the points mentioned above, vaccination rates for the
seasonal influenza vaccine have never been published in Malta.
Whilst there are difficulties with estimating coverage due to the
segmented nature of the Maltese general practice system, more
concerted efforts need to be made. Knowing current vaccination
rates should help in planning how to vaccinate nearly 400,000
persons once a pandemic vaccine is available. The fact that a
pandemic vaccine will probably be available as two doses will
only serve to complicate matters.
It is unfortunate that data describing the risk profile of the
Maltese populations in not readily available and it is not
necessarily correct to model effects on the Maltese population
using data derived from other countries. The high rates of certain
chronic illnesses like diabetes mellitus in the Maltese population
make such comparisons even more tenuous. It is also arguable
that consultation rates with general practitioners in Malta and
in the United States are the same. Health authorities need to
understand that good quality research, both now, and in the
early stages of a local response to the pandemic, is essential to
provide an effective response to a pandemic.
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